For customers outside of Japan
EPS was established as a CRO in Japan in 1991. Since then, EPS was the first Japanese CRO to establish a subsidiary in China and to provide clinical development support services centered on Asia-Pacific. The EPS Group of affiliated companies has built a one-stop platform of solutions to support not only clinical development but also all services from clinical development to post-marketing in Japan. EPS Corporation. (EPS), an EPS Group Company, serves as a gateway between Japan and the rest of the world and provides the one-stop platform solutions developed in Japan to customers around the world.
EPS continues to provide solutions for the implementation of high-quality Asian and global clinical trials through business alliances with its subsidiaries and affiliates in Asia and with world-class CROs based in Europe, USA, and India. In April 2019, we formed a strategic business alliance with George Clinical Pty Ltd., headquartered in Australia.
In general, pharmaceutical and medical device companies are manufacturing companies that manufacture and sell drugs and devices while CROs are service and solutions companies that provide clinical development operations as its offering to clients. What we, as a service and solutions company, should aim for is to continuously provide stable services and solutions through process standardization and improvement. Nowadays, the establishment of a system that can continuously provide stable services is highly regarded as a valued technology.
We will continue to practice the company's basic philosophy of “Contribute to the health industry through the creation of valuable solutions” and continue to search for optimal solutions with our customers. This is the spirit of the EPS “Ever Progressing System”, which is the origin of the company name. It is expected that the people who work here will grow while constantly changing and evolving. And that is what everyone expects.
We will continue to respond to your needs. Thank you for your continued support and guidance.
Share this page